Last $62.14 USD
Change Today +0.71 / 1.16%
Volume 1.5M
DGX On Other Exchanges
Symbol
Exchange
New York
Stuttgart
As of 8:04 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3 Giralda Farms

Madison, NJ 07940

United States

Phone: 973-520-2700

Fax:

structure and its diseases); immunogenetics and human leukocyte antigens (solid organ and bone marrow transplantation, eligibility for vaccines, selection of pharmacotherapeutic agents and immunotherapy); immunology (the study of the immune system, including antibodies, cytokines, immune system cells and their effect, receptor systems and autoimmune diseases); microbiology and infectious diseases (the study of microscopic forms of life, including parasites, bacteria, viruses, fungi, and other infectious agents); oncology (the study of abnormal cell growth, including benign tumors and cancer); serology (a science dealing with body fluids and their analysis, including antibodies, proteins, and other characteristics); and toxicology (the study of chemicals and drugs and their adverse effects on the body). The company also offers gene-based testing services for the predisposition, diagnosis, treatment, and monitoring of cancers. It provides integrated diagnostic information services that include both anatomic pathology and clinical pathology testing, enabling its pathologists to offer patients and physicians a complete analysis. The company provides its services through its nationwide network of major laboratories, anatomic pathology laboratories, and response laboratories. It also provides routine testing services, and inpatient anatomic pathology and medical director services, at hospital laboratories. Majority of the company’s services are provided under the Quest Diagnostics brand. The company also provides services under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, and Athena Diagnostics brands. Focus Diagnostics is a major provider of infectious disease diagnostic information services. Through Athena Diagnostics, the company has a position in the improving neurology diagnostics market. The company has a position in advanced cardiovascular diagnostic information services, including its CardioIQ offering. It offers the Leumeta family of tests for leukemia and lymphoma. International The company provides diagnostic information services in various markets outside the United States. Connectivity The company offers connectivity solutions that provide ordering and reporting of diagnostic information services, convenience in electronically prescribing medication and access to information. The majority of diagnostic information that the company provides is delivered electronically, including by taking advantage of its Care360 products. These products, including Care360 Labs and Meds, enable physicians electronically to order diagnostic testing and review test results from the company and electronically to prescribe medication. Its Care360 Mobile application allows physicians to review diagnostic information and order medications using their smartphones or mobile devices. The company also provides patients with tools to manage their healthcare and medical information. It also offers TestMinder, which sends email reminders to patients who require frequent testing; and Gazelle, a mobile health platform that allows users to receive and archive their Quest Diagnostics test results, manage their personal health information, find a Quest Diagnostics location and schedule appointments directly from their smartphone. The company collaborates with the University of California, San Francisco, the university focused on health, to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine. It has collaboration with the U.S. Centers for Disease Control and Prevention to improve public health analysis of hepatitis C screening, diagnosis and treatment, based on analysis of its national hepatitis C virus diagnostic information. During 2013, the company introduced approximately 75 new or enhanced tests and disease area solutions, such as: Cancer: The company introduced next generation sequencing testing to aid in the diagnosis of leukemia. It also introduced tissue-based microarray testing for solid tumors and a specific application for melanoma. In addition, the company introduced its BRCAvantage solution for genetic mutations in BRCA1 and 2 genes to

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $62.14 USD +0.71

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $86.89 USD +0.23
Hologic Inc $25.26 USD -0.37
Laboratory Corp of America Holdings $106.06 USD -0.04
Myriad Genetics Inc $37.02 USD -0.33
QIAGEN NV €18.43 EUR +0.006
View Industry Companies
 

Industry Analysis

DGX

Industry Average

Valuation DGX Industry Range
Price/Earnings 11.7x
Price/Sales 1.2x
Price/Book 3.3x
Price/Cash Flow 10.3x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit www.questdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.